Karanges EA[au] - Search Results

Year	Number of Results
2013	1
2014	1
2015	1
2016	3
2017	4
2018	5
2019	5
2020	3
2021	5
2022	2

1

The changing face of Australian data reforms: impact on pharmacoepidemiology research.

de Oliveira Costa J, Bruno C, Schaffer AL, Raichand S, Karanges EA, Pearson SA. de Oliveira Costa J, et al. Among authors: karanges ea. Int J Popul Data Sci. 2021 Apr 15;6(1):1418. doi: 10.23889/ijpds.v6i1.1418. Int J Popul Data Sci. 2021. PMID: 34007904 Free PMC article.

2

Pharmaceutical industry payments and assisted reproduction in Australia: a retrospective observational study.

Karanges EA, Nangla C, Parker L, Fabbri A, Farquhar C, Bero L. Karanges EA, et al. BMJ Open. 2021 Aug 31;11(9):e049710. doi: 10.1136/bmjopen-2021-049710. BMJ Open. 2021. PMID: 34465582 Free PMC article.

3

A comparison of educational events for physicians and nurses in Australia sponsored by opioid manufacturers.

Grundy Q, Mazzarello S, Brennenstuhl S, Karanges EA. Grundy Q, et al. Among authors: karanges ea. PLoS One. 2021 Mar 18;16(3):e0248238. doi: 10.1371/journal.pone.0248238. eCollection 2021. PLoS One. 2021. PMID: 33735203 Free PMC article.

4

"There are ways … drug companies will get into DTC decisions": How Australian drug and therapeutics committees address pharmaceutical industry influence.

Parker L, Bennett A, Mintzes B, Grundy Q, Fabbri A, Karanges EA, Bero L. Parker L, et al. Among authors: karanges ea. Br J Clin Pharmacol. 2021 May;87(5):2341-2353. doi: 10.1111/bcp.14636. Epub 2020 Nov 26. Br J Clin Pharmacol. 2021. PMID: 33129226 Free article.

5

Australian Clinical Trial Authors' Declarations of Industry Ties.

Flood L, Mintzes B, Chiu K, Dai Z, Karanges EA, Holman B. Flood L, et al. Among authors: karanges ea. J Gen Intern Med. 2022 Mar 7. doi: 10.1007/s11606-022-07466-9. Online ahead of print. J Gen Intern Med. 2022. PMID: 35257257 No abstract available.

6

Policies affecting the supply and access of opioid analgesics: a scoping review protocol.

Chiu K, McDonald S, Legg T, Karanges EA, Bero L. Chiu K, et al. Among authors: karanges ea. JBI Evid Synth. 2020 May;18(5):1124-1134. doi: 10.11124/JBISRIR-D-19-00095. JBI Evid Synth. 2020. PMID: 32813367

7

Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes.

Karanges EA, Ting N, Parker L, Fabbri A, Bero L. Karanges EA, et al. Aust J Gen Pract. 2020 Mar;49(3):151-154. doi: 10.31128/AJGP-08-19-5041. Aust J Gen Pract. 2020. PMID: 32113215 Free article.

8

Understanding the Nature and Extent of Pharmaceutical Industry Payments to Nonphysician Clinicians.

Karanges EA, Grundy Q, Bero L. Karanges EA, et al. JAMA Intern Med. 2019 Oct 1;179(10):1430-1432. doi: 10.1001/jamainternmed.2019.1371. JAMA Intern Med. 2019. PMID: 31180446 Free PMC article.

9

Trends in opioid utilisation in Australia, 2006-2015: Insights from multiple metrics.

Karanges EA, Buckley NA, Brett J, Blanch B, Litchfield M, Degenhardt L, Pearson SA. Karanges EA, et al. Pharmacoepidemiol Drug Saf. 2018 May;27(5):504-512. doi: 10.1002/pds.4369. Epub 2017 Dec 27. Pharmacoepidemiol Drug Saf. 2018. PMID: 29280224

10

Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.

Parker L, Karanges EA, Bero L. Parker L, et al. Among authors: karanges ea. BMJ Open. 2019 Feb 19;9(2):e024928. doi: 10.1136/bmjopen-2018-024928. BMJ Open. 2019. PMID: 30782921 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results